Which has better valuation & earnings, VSTM or BHVN?

Verastem has higher revenue and earnings than Biohaven. Verastem is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 20.75 -$209.47M -$2.66 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is VSTM or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Verastem's return on equity of -492.59% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -492.59% -93.39% Biohaven N/A -866.46% -137.99%

Does the media refer more to VSTM or BHVN?

In the previous week, Verastem had 4 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for Verastem and 7 mentions for Biohaven. Verastem's average media sentiment score of 0.53 beat Biohaven's score of 0.03 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PVLA or VSTM?

In the previous week, Palvella Therapeutics had 8 more articles in the media than Verastem. MarketBeat recorded 19 mentions for Palvella Therapeutics and 11 mentions for Verastem. Verastem's average media sentiment score of 0.53 beat Palvella Therapeutics' score of -0.24 indicating that Verastem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, VSTM or ZBIO?

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 20.75 -$209.47M -$2.66 N/A Zenas BioPharma $10M 197.25 -$377.74M -$8.47 N/A

Is VSTM or ZBIO more profitable?

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -492.59% -93.39% Zenas BioPharma N/A -99.99% -58.06%

Does the media favor VSTM or ZBIO?

In the previous week, Verastem had 9 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for Verastem and 2 mentions for Zenas BioPharma. Verastem's average media sentiment score of 0.53 beat Zenas BioPharma's score of 0.00 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLS or VSTM?

In the previous week, Verastem had 9 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 11 mentions for Verastem and 2 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.44 beat Verastem's score of 0.53 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, VSTM or ADMA?

ADMA Biologics has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 20.75 -$209.47M -$2.66 N/A ADMA Biologics $512.28M 4.49 $146.93M $0.70 14.18

Is VSTM or ADMA more profitable?

ADMA Biologics has a net margin of 32.98% compared to Verastem's net margin of -231.59%. ADMA Biologics' return on equity of 40.17% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -492.59% -93.39% ADMA Biologics 32.98% 40.17% 26.97%

Does the media refer more to VSTM or ADMA?

In the previous week, ADMA Biologics had 35 more articles in the media than Verastem. MarketBeat recorded 46 mentions for ADMA Biologics and 11 mentions for Verastem. Verastem's average media sentiment score of 0.53 beat ADMA Biologics' score of 0.06 indicating that Verastem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 7 Very Positive mention(s) 3 Positive mention(s) 31 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Verastem (VSTM) Competitors

$7.08 +0.29 (+4.32%)

As of 10:47 AM Eastern

Compare

VSTM vs. BHVN, PVLA, ZBIO, SLS, and ADMA

Should you buy Verastem stock or one of its competitors? Verastem's main competitors and comparable companies include Biohaven (BHVN), Palvella Therapeutics (PVLA), Zenas BioPharma (ZBIO), SELLAS Life Sciences Group (SLS), and ADMA Biologics (ADMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Verastem compare to Biohaven?

Verastem (NASDAQ:VSTM) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

In the previous week, Verastem had 4 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for Verastem and 7 mentions for Biohaven. Verastem's average media sentiment score of 0.53 beat Biohaven's score of 0.03 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Verastem presently has a consensus price target of $13.83, indicating a potential upside of 95.30%. Biohaven has a consensus price target of $21.63, indicating a potential upside of 52.93%. Given Verastem's stronger consensus rating and higher probable upside, equities research analysts clearly believe Verastem is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

88.4% of Verastem shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Verastem has higher revenue and earnings than Biohaven. Verastem is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	20.75	-$209.47M	-$2.66	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Biohaven has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Verastem's return on equity of -492.59% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-492.59%	-93.39%
Biohaven	N/A	-866.46%	-137.99%

Summary

Verastem beats Biohaven on 9 of the 15 factors compared between the two stocks.

How does Verastem compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Palvella Therapeutics has higher revenue and earnings than Verastem. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	51.93	-$41.72M	-$4.83	N/A
Verastem	$30.91M	20.75	-$209.47M	-$2.66	N/A

Palvella Therapeutics has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Palvella Therapeutics' return on equity of -47.84% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Verastem	-231.59%	-492.59%	-93.39%

In the previous week, Palvella Therapeutics had 8 more articles in the media than Verastem. MarketBeat recorded 19 mentions for Palvella Therapeutics and 11 mentions for Verastem. Verastem's average media sentiment score of 0.53 beat Palvella Therapeutics' score of -0.24 indicating that Verastem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics presently has a consensus target price of $209.14, indicating a potential upside of 35.57%. Verastem has a consensus target price of $13.83, indicating a potential upside of 95.30%. Given Verastem's higher possible upside, analysts clearly believe Verastem is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Palvella Therapeutics has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, Verastem has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Palvella Therapeutics beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Zenas BioPharma?

Verastem (NASDAQ:VSTM) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-492.59%	-93.39%
Zenas BioPharma	N/A	-99.99%	-58.06%

In the previous week, Verastem had 9 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for Verastem and 2 mentions for Zenas BioPharma. Verastem's average media sentiment score of 0.53 beat Zenas BioPharma's score of 0.00 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	20.75	-$209.47M	-$2.66	N/A
Zenas BioPharma	$10M	197.25	-$377.74M	-$8.47	N/A

88.4% of Verastem shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Verastem currently has a consensus target price of $13.83, indicating a potential upside of 95.30%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 41.74%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Verastem has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, suggesting that its share price is 203% less volatile than the broader market.

Summary

Verastem beats Zenas BioPharma on 12 of the 17 factors compared between the two stocks.

How does Verastem compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Verastem. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Verastem	$30.91M	20.75	-$209.47M	-$2.66	N/A

SELLAS Life Sciences Group has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Verastem has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Verastem had 9 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 11 mentions for Verastem and 2 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.44 beat Verastem's score of 0.53 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential downside of 9.12%. Verastem has a consensus target price of $13.83, suggesting a potential upside of 95.30%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

SELLAS Life Sciences Group has a net margin of 0.00% compared to Verastem's net margin of -231.59%. SELLAS Life Sciences Group's return on equity of -47.12% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Verastem	-231.59%	-492.59%	-93.39%

Summary

Verastem beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.

How does Verastem compare to ADMA Biologics?

Verastem (NASDAQ:VSTM) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, ADMA Biologics had 35 more articles in the media than Verastem. MarketBeat recorded 46 mentions for ADMA Biologics and 11 mentions for Verastem. Verastem's average media sentiment score of 0.53 beat ADMA Biologics' score of 0.06 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	7 Very Positive mention(s)	3 Positive mention(s)	31 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Verastem's net margin of -231.59%. ADMA Biologics' return on equity of 40.17% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-492.59%	-93.39%
ADMA Biologics	32.98%	40.17%	26.97%

Verastem presently has a consensus price target of $13.83, indicating a potential upside of 95.30%. ADMA Biologics has a consensus price target of $18.67, indicating a potential upside of 88.08%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Verastem is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ADMA Biologics has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	20.75	-$209.47M	-$2.66	N/A
ADMA Biologics	$512.28M	4.49	$146.93M	$0.70	14.18

88.4% of Verastem shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats Verastem on 10 of the 17 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$640.53M	$3.75B	$7.08B	$12.90B
Dividend Yield	N/A	3.77%	2.58%	10.06%
P/E Ratio	-2.66	9.15	269.01	24.78
Price / Sales	20.75	1,262.34	586.37	95.48
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	9.57	18.15	11.45	6.45
Net Income	-$209.47M	-$13.25M	$3.44B	$346.92M
7 Day Performance	21.91%	3.55%	2.37%	0.93%
1 Month Performance	28.08%	-1.27%	-0.07%	-0.64%
1 Year Performance	-8.01%	62.25%	75.97%	22.23%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	3.5868 of 5 stars	$7.08 +4.3%	$13.83 +95.3%	+0.7%	$640.53M	$30.91M	N/A	50	Earnings Report Analyst Forecast
BHVN Biohaven	3.5035 of 5 stars	$13.40 -0.7%	$21.63 +61.3%	-1.0%	$2.03B	N/A	N/A	239	News Coverage Earnings Report Gap Down
PVLA Palvella Therapeutics	3.0165 of 5 stars	$140.78 +1.3%	$207.36 +47.3%	+272.2%	$1.99B	$42.81M	N/A	N/A	Earnings Report
ZBIO Zenas BioPharma	2.9764 of 5 stars	$31.13 -1.0%	$44.29 +42.3%	+118.7%	$1.98B	$10M	N/A	N/A
SLS SELLAS Life Sciences Group	1.0657 of 5 stars	$11.22 +12.1%	$10.00 -10.9%	+598.7%	$1.97B	N/A	N/A	10	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. BHVN, PVLA, ZBIO, SLS, and ADMA

How does Verastem compare to Biohaven?

Summary

How does Verastem compare to Palvella Therapeutics?

Summary

How does Verastem compare to Zenas BioPharma?

Summary

How does Verastem compare to SELLAS Life Sciences Group?

Summary

How does Verastem compare to ADMA Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. BHVN, PVLA, ZBIO, SLS, and ADMA

How does Verastem compare to Biohaven?

Does the media refer more to VSTM or BHVN?

Which has more volatility & risk, VSTM or BHVN?

Do analysts recommend VSTM or BHVN?

Do insiders and institutionals believe in VSTM or BHVN?

Which has better valuation & earnings, VSTM or BHVN?

Is VSTM or BHVN more profitable?

Summary

How does Verastem compare to Palvella Therapeutics?

Which has better earnings & valuation, PVLA or VSTM?

Is PVLA or VSTM more profitable?

Does the media favor PVLA or VSTM?

Do analysts rate PVLA or VSTM?

Which has more risk and volatility, PVLA or VSTM?

Do institutionals and insiders hold more shares of PVLA or VSTM?

Summary

How does Verastem compare to Zenas BioPharma?

Is VSTM or ZBIO more profitable?

Does the media favor VSTM or ZBIO?

Which has better valuation & earnings, VSTM or ZBIO?

Do insiders & institutionals believe in VSTM or ZBIO?

Do analysts recommend VSTM or ZBIO?

Which has more risk & volatility, VSTM or ZBIO?

Summary

How does Verastem compare to SELLAS Life Sciences Group?

Which has better valuation & earnings, SLS or VSTM?

Which has more volatility & risk, SLS or VSTM?

Do insiders and institutionals hold more shares of SLS or VSTM?

Does the media prefer SLS or VSTM?

Do analysts recommend SLS or VSTM?

Is SLS or VSTM more profitable?

Summary

How does Verastem compare to ADMA Biologics?

Does the media refer more to VSTM or ADMA?

Which has more risk & volatility, VSTM or ADMA?

Is VSTM or ADMA more profitable?

Do analysts recommend VSTM or ADMA?

Which has better earnings & valuation, VSTM or ADMA?

Do insiders & institutionals believe in VSTM or ADMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools